Premium
INCREASE OF THE IN VITRO COMPLEMENT‐DEPENDENT CYTOTOXICITY AGAINST AUTOLOGOUS INVASIVE HUMAN BLADDER TUMOR CELLS BY NEURAMINIDASE TREATMENT
Author(s) -
Jacobsen Flemming
Publication year - 1982
Publication title -
acta pathologica microbiologica scandinavica series c: immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0108-0202
DOI - 10.1111/j.1699-0463.1982.tb01437.x
Subject(s) - cytolysis , neuraminidase , cytotoxicity , complement dependent cytotoxicity , in vitro , tumor cells , immunology , cancer research , complement system , antibody , biology , chemistry , antibody dependent cell mediated cytotoxicity , biochemistry , virus
Complement‐dependent cytotoxicity (CDC) was measured in a 51‐Cr release assay against tumor cells from 13 non‐invasive and 7 invasive transitional‐cell tumors of the urinary bladder. CDC was compared between mechanically dispersed tumor cells and neuraminidase‐treated tumor cells. Neuraminidase treatment of bladder tumor cells enhanced their susceptibility to complement‐dependent cytolysis. There were no differences in CDC between autologous and allogenic sera. Mechanically dispersed tumor cells showed no significant differences in susceptibility when non‐invasive and invasive tumor cells were compared, whereas significant differences in CDC were seen when neuraminidase‐treated non‐invasive and invasive tumor cells were used as targets. A C2 deficient serum showed significantly reduced cytotoxicity suggesting that the CDC reaction requires classical complement activation. A hypogammaglobulinemic serum showed stronger CDC compared to autologous and other allogenic sera and upon dilution of autologous sera and hypogammaglobulinemic serum CDC declined parallelly.